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Abstract
sp2-Iminosugar-type castanospermine analogues have been shown to exhibit anti-tumor activity. However, their effects on
cell proliferation and apoptosis and the molecular mechanism at play are not fully understood. Here, we investigated the
effect of two representatives, namely the pseudo-S- and C-octyl glycoside 2-oxa-3-oxocastanospermine derivatives SO-OCS
and CO-OCS, on MCF-7 and MDA-MB-231 breast cancer and MCF-10A mammary normal cell lines. We found that SO-OCS
and CO-OCS inhibited breast cancer cell viability in a concentration- and time-dependent manner. This effect is specific to
breast cancer cells as both molecules had no impact on normal MCF-10A cell proliferation. Both drugs induced a cell cycle
arrest. CO-OCS arrested cell cycle at G1 and G2/M in MCF-7 and MDA-MB-231cells respectively. In MCF-7 cells, the G1 arrest
is associated with a reduction of CDK4 (cyclin-dependent kinase 4), cyclin D1 and cyclin E expression, pRb phosphorylation,
and an overexpression of p21Waf1/Cip1. In MDA-MB-231 cells, CO-OCS reduced CDK1 but not cyclin B1 expression. SO-OCS
accumulated cells in G2/M in both cell lines and this blockade was accompanied by a decrease of CDK1, but not cyclin B1
expression. Furthermore, both drugs induced apoptosis as demonstrated by the increased percentage of annexin V positive
cells and Bax/Bcl-2 ratio. Interestingly, in normal MCF-10A cells the two drugs failed to modify cell proliferation, cell cycle
progression, cyclins, or CDKs expression. These results demonstrate that the effect of CO-OCS and SO-OCS is triggered by
both cell cycle arrest and apoptosis, suggesting that these castanospermine analogues may constitute potential anti-cancer
agents against breast cancer.
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Introduction
Cancer development is often due to perturbations in the cell
cycle that lead to unlimited proliferation and confers apoptosis
resistance to cancer cells [1,2]. The progression of cells through
the cell cycle is exerted by cyclin, cyclin-dependent kinases
(CDKs), and CDK inhibitors (CKIs). The cyclin-CDK complexes
govern a progression of the events that lead cells from a resting
state (G0) to growth phase (G1), DNA replication phase (S), and
finally to cell division (M). Cyclin D and cyclin E, in association
with CDK4 and CDK6, contribute to the G1/S transition,
whereas inhibition of the kinase activity of cyclin/CDK complex is
mediated by several CKIs, including p21waf1/cip1 and p27kip1 [3].
Cyclins A and B (along with Cdc2) are important for entry of the
cells into the M phase [4]. Aberrantly expressed cell cycle-related
cyclins are highly associated with breast cancer [5]. Indeed, cyclin
D1 is overexpressed in approximately 50% of breast cancers and is
associated with an aggressive tumor phenotype and specific types
of p53 [6,7,8]. Cyclin E is overexpressed in 30% of breast tumors
[9]. Moreover, overexpression of cyclin B1 has also been reported
in various human tumors, including breast cancer [10].
Defective apoptosis represents a major causative factor in the
development and progression of cancer. Indeed, the majority of
chemotherapeutic agents act through the apoptotic pathway to
induce cancer cell death. Moreover, resistance to chemothera-
peutic strategies seems to be due to alterations in the apoptotic
pathway of cancer cells [11]. A factor which is consistently
implicated in apoptosis is one of the Bcl2 extended family
members [12]. Thus, the anti-apoptotic protein Bcl-2 is expressed
in 25% to 50% of breast cancer [13]. Bcl-2 expression has been
cited as a favorable prognostic marker [14] and its expression has
been shown to be associated with improved survival among
patients with breast cancer [14,15,16].
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e76411
Protein glycosylation starts in the endoplasmic reticulum (ER)
with a series of steps conserved in the majority of eukaryotes
[17,18]. Glycosidases (I and II) act to sequentially remove the
glucose residues from the N-glycan in the ER [17,18]. In a
concerted manner, Glucosidases I and II along with lectin
chaperones calnexin and calreticulin participate to the ER-
retention of nascent glycoproteins until they are properly folded
and thus preventing their aggregation [19]. Polypeptides that
succeed in reaching their mature conformation are released from
the lectin-proteins as soon as their folding process is completed
[20,21], and the unfolded and or misfolded glycoproteins are
delivered to cytosolic degradation mediated by the ubiquitin-
proteasome pathway, a process known as an ER-associated
degradation (ERAD) [22,23,24]. Moreover, accumulation of
unfolded proteins in the ER induces a condition known as ER
stress that in turn, triggers the increased expression of BiP and
other chaperones, a phenomenon termed ‘‘unfolded protein
response’’ (UPR) [25]. The increased synthesis of ER chaperones,
which serve to correct protein misfolding, occurs concomitantly
with a marked decrease in the rate of overall protein synthesis
[26]. and along with cell arrest in G1 phase of the cell cycle
[27,28]. Inhibition of protein synthesis lowers the overall rate of
protein traffic into the ER, thus limiting damage to this organelle.
However, If ER stress persists; cells activate mechanisms that
result in cell death. Aberrant glycosylation of glycoproteins and
glycolipids is a typical molecular feature of malignant cells. For
instance, in breast cancer deregulation of the enzymes involved in
N-glycosylation of proteins leads to massive formation of
polylactosamine chains. These polysaccharides are involved in
tumor progression, including proliferation, migration, invasion
and angiogenesis [29].
Most efforts up to now have focused in the use of iminosugar
inhibitors of the neutral a-glucosidases I and II or a-mannosidase
II, such as 1-deoxynojirimycin and castanospermine or swainso-
nine. A significant reduction in tumor progression and metastasis
has been observed in several cases in vitro and in vivo
[30,31,32,33,34], although, the mechanisms underlying the anti-
proliferative action of these substances remain unknown. A new
generation of iminosugar-type glycosidase inhibitors termed sp2-
iminosugars was conceived [35,36]. Contrary to most classical
iminosugars, sp2-iminosugars present more affinity towards human
glycosidases [37,38,39,40]. Recently, the sp2-iminosugar-type 2-
oxa-3-oxocastanospermine N-, S-, and C-octyl glycoside derivatives
were identified as selective inhibitors of neutral a-glucosidases and
evaluated for their anti-growth activity in MCF-7 breast cancer
cell line [41]. Whereas the N-glycoside NO-OCS had only a
modest effect, the S- and C-glycoside congeners SO-OCS and CO-
OCS showed a significant anti-proliferative effect with a concom-
itant increased in cell mortality [41].
Herein, we report a study on the effect of both SO-OCS and
CO-OCS in cell proliferation and apoptosis on MCF-7 and MDA-
MB-231 Breast cancer (BC) cells, and normal breast MCF-10A
cells and their associated-mechanisms. We demonstrate that both
sp2-iminosugar derivatives induce cell cycle arrest in BC cell lines.
CO-OCS induced an arrest at G0/G1 and G2/M transitions in
MCF-7 and MDA-MB-231 cells respectively. In contrast, SO-
OCS induced an arrest at G2/M in both cell lines. We identified
cyclin D1, cyclin E, CDK1 and 4, pRb and p21waf1/cip1 as key
potential mediators in CO-OCS and SO-OCS-induced cell cycle
arrest. Moreover, both drugs induced apoptosis by regulating Bcl2
and Bax expression. Interestingly, neither SO-OCS nor CO-OCS
affected breast normal cell proliferation and apoptosis.
Materials and Methods
Drug
The 2-oxa-3-oxocastanospermine pseudo-S- and C-octyl glyco-
sides SO-OCS and CO-OCS (Fig. 1A) were synthesized from
acetylated pseudo-glycosyl donor precursors bearing a psudo-
anomeric acetoxy (for SO-OCS) or fluoro group (for CO-OCS) by
S-glycosylation with octanethiol or C-glycosylation with trio-
ctylaluminum, respectively, following the procedures previously
reported [41]. The compounds were solved in DMSO, before
storage at –20uC.
Cell culture
MCF-7 and MDA-MB-231 BC cells were grown in Eagle’s
minimum essential medium (EMEM), supplemented with 5% fetal
calf serum (Lonza, Levallois-Perret, France), 2 mM L-glutamine,
and 0.06% HEPES. The immortalized human mammary
epithelial cell line MCF-10A was cultured in complete MCF-
10A growth medium, composed of Dulbecco’s modified Eagle’s
medium/nutrient mixture F12 (DMEM/F12) supplemented with
5% fetal calf serum, 20 ng/ml epidermal growth factor, 10 mg/ml
insulin, 0.5 mg/ml hydrocortisone, and 100 ng/ml cholera toxin
(Sigma-Aldrich, St-Quentin Fallavier, France). All cell lines were
grown in a 5% CO2-humidified incubator at 37 uC.
Cell viability and mortality
Cells were grown in six petri-dishes (Ø 35 cm) for 2 days, then
incubated with SO-COS or CO-COS at different concentrations
for 3 days (20, 30, 40, 50, 100 mM). The cells viability and
mortality were then assessed by Trypan Bleu assay 72-h after
treatment. Cells were harvested by trypsinization and diluted in
trypan Blue solution. Cells viability and mortality were assessed
using the standard Malassez cell method. Cell counts were
performed six times (in a blind manner) and the results were
expressed as the percentage of cells (alive or dead) counted
normalized to control.
Flow cytometric analysis
After drug treatment for 72-h at a concentration of 40 mM, the
cells were removed by trypsinization, washed twice with
phosphate-buffered saline (PBS), then pellets were re-suspended
in 300 mL PBS/EDTA and fixed with 700 mL absolute ethanol at
220uC for one day. The cells were treated with ribonuclease
(RNA-ease) at concentration 10 mg/ml for 30 min at room
temperature and stained with propidium-iodide (PI), (Sigma-
Aldrich). The percentage of cells in different phases was measured
by flow cytometry with AccuriH and cyflogic system.
Western Blotting analysis
Whole-cell lysates were prepared with 1% sodium dodecyl
sulfate and a protease inhibitor cocktail (Sigma-Aldrich). Proteins
were separated by denaturing SDS–PAGE and transferred onto
nitrocellulose membranes [42]. The primary antibodies used were:
anti-CDK2 (1:2,000), anti-CDK4 (1:1,200), anti-cyclin E (1:1,200,
Santa Cruz Biotechnology, Inc., Heidelberg, Germany), anti-
cyclin D1 and anti-p21Waf1/Cip1 (1:500, Cell Signalling Tech.,
Danvers, MA), b-actin (used as internal standard, Santa Cruz
Biotechnology), anti- protein pRb (1:1000), phospho-pRb (1:500),
p27kip1 (1:1000), anti-Bcl-2 (1:1,000), anti-CDK1(cdc2)(1:1,000),
and cyclin B1(1:2,000) (Cell Signaling Tech), anti-Bax (1:1,000)
(BD Biosciences). Antibodies are followed by secondary antibodies
coupled to horseradish peroxidase. Bands were detected using an
enhanced chemiluminescence kit (GE Healthcare, Saclay, France)
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and quantified using the densitometric analysis option in the Bio-
Rad image acquisition system (Bio-Rad Laboratories).
Quantitative apoptosis analysis
Apoptotic cells were detected by performing FITC annexin V
apoptosis detection Kit II staining (BD pharmingen). After 72-h of
incubation with SO-OCS or CO-OCS at 40 mM, cells were
collected, washed twice in ice-cold PBS and re-suspended in 1x
binding buffer. FITC annexin V and propidium iodide (PI) were
added to the cell preparation and incubated for 15 min at room
temperature in the dark. Binding buffer was added to each tube
and then the samples were analyzed by flow cytometry (AccuriH).
Statistical analysis
Results were expressed as means6 SD, statistical analysis of the
data were performed using two-tailed unpaired (between two
groups) or a one way analysis of variance (ANOVA, among three
or more groups). We compared the mean of each group with that
of the control. Differences were considered significant when p
value is , 0.05.
Results
CO-OCS and SO-OCS decrease breast cancer cell growth
but not affect proliferation of normal breast cells
We investigated the sensitivity of breast cancer and breast
normal cell lines to the sp2-iminosugar glycosides CO-OCS and
SO-OCS using the Trypan Blue exclusion assay. Both CO-OCS
and SO-OCS inhibited cell viability in a dose dependent manner.
IC50 values, determined after treatment in complete medium for
72-h, are shown in Table 1. MCF-7 cells were more sensitive to
the C-glycoside CO-OCS than to the S-glycoside SO-OCS (Figure
1B), while MDA-MB-231 cells showed similar sensitivity to both
compounds (Figure 1C). We also estimated cell mortality under
the same conditions. CO-OCS increased cell mortality from a
concentration of 30 mM for MCF-7 (Figure 1D) and MDA-MB-
231 cells (Figure 1E). SO-OCS induced less mortality than CO-
OCS in both cancer cell lines (less than 20% at 100 mM).
Figure 1. CO-OCS and SO-OCS reduced cell viability and induced mortality in breast cancer cell lines but not in normal ones. Cells
are treated with various concentrations of CO-OCS and SO-OCS (0–100 mM) for 72-h. A, Structures of the sp2-iminosugar-type S-octyl and C-octyl 2-
oxa-3-oxocastanospermine glycosides SO-OCS and CO-OCS, respectively, evaluated in this work. Inhibitory effects of CO-OCS and SO-OCS on MCF-7
(B) and MDA-MB-231 cells (C). Results were expressed as percentage of the controls, which were arbitrarily assigned 100% viability. CO-OCS and SO-
OCS increased cell mortality in MCF-7 (D) and MDA-MB-231 cells (E). Neither CO-OCS nor SO-OCS affects the cell viability (F) and the mortality (G) of
MCF 10-A cells. The values indicated are mean 6 SD of three independent experiments and analyses by ANOVA test *p,0.05, **p,0.01, ***p,0.001.
compared with control group
doi:10.1371/journal.pone.0076411.g001
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Interestingly, CO-OCS as well as SO-OCS failed to affect both
viability and mortality of normal MCF-10A cells at concentrations
up to 100 mM (Figure 1F-G).
CO-OCS and SO-OCS reduce cell proliferation by
inducing cell cycle arrest
To investigate the mechanism accounting for the anti-prolifer-
ative activity of CO-OCS and SO-OCS, the cell cycle distribution
was analyzed in both normal and cancer breast cell lines. All cells
were treated for 72-h with the corresponding sp2-iminosugar
glycoside at 40 mM. As determined by flow cytometry, MCF-7
treatment by CO-OCS resulted in a clear increase in cell
percentage in G1 phase and G2/M with a concomitant decrease
in the percentage of cells in the S phase when compared with
control (Figure 2A, p,0.001). The same treatment accumulated
cells in G2/M in MDA-MB-231 cells, with a decrease of cells in
G1 and S phases when compared to control (Figure 2B, p,0.001).
Otherwise, the thio-glycoside SO-OCS induced accumulation of
cells in G2/M with a decrease of cells in G1 and S phases in both
MCF-7 and MDA-MB-231 cells (Figure 2C, D, p,0.001). Table 2
shows the percentage of cells in the cell cycle under different
conditions. Similar experiments were performed on normal MCF-
10 A cells and, interestingly, no significant effect was observed on
cell cycle distribution after 72-h of treatment with CO-OCS
(Figure 2E) or SO-OCS (Figure 2F). These data are consistent with
an induction of cell arrest in G1 and G2/M by CO-OCS and SO-
OCS, respectively.
CO-OCS and SO-OCS regulate the expression of cell cycle
proteins involved in G1 and G2/M phases
To elucidate the molecular mechanisms involved in the
observed cell cycle alterations, we investigated the effect of CO-
OCS and SO-OCS on the expression of cell cycle protein actors.
We focused on the proteins that play a crucial role in G1 and G2/
M phases. It is known that cyclins D1, E and CDK4/CDK2 and
pRb proteins play an important role in controlling the G1
progression and G1?S transition of the cell cycle [43] and cyclin
B1 and Cdc42 (CDK1) in G2/M [44,45]. Compounds that reduce
the expression and or activity of these proteins could be expected
to reduce breast cancer cell proliferation.
Cells were treated with the sp2-iminosugars at 40 mM concen-
tration for 72-h. They were then harvested by RIPA and the cell
cycle proteins levels were analyzed by western blotting. In MCF-7
cells, the pseudo-C-glycoside CO-OCS decreased the expression of
cyclin D1, cyclin E, and CDK4 by 82%, 51% and 64%
respectively (Figure 3A). Moreover, it reduced phopshorylation
of pRb by 46% (Figure 3B) and increased the expression of
p21Waf1/Cip1 by 2.2 folds over control (Figure 3C). The pseudo-S-
glycoside SO-OCS decreased CDK1 expression by 81%, but
failed to affect cyclin B1 expression (Figure 3D). Treatment of
MDA-MB-231 cells by CO-OCS or SO-OCS decreased CDK1
expression by 67% and 49% respectively, but was without any
effect on cyclin B1 expression (Figure 4 A, B). Finally, similar
experiments have been performed on MCF-10 A cells and no
effect was observed on the expression of CDK4, CDK1, cyclins
D1, E, and B1 (Figure 4C).
CO-OCS induces apoptosis in MCF-7 and MDA-MB-
231cell lines, while SO-OCS induces apoptosis only in
MCF-7 cells
Since the pseudo-C-glycoside CO-OCS induces more cell
mortality in BC cell lines than the pseudo-S-glycoside analogue
SO-OCS, it was of interest to establish whether this mortality is
attributed to apoptosis. Both MCF-7 and MDA-MB-231 cells
were treated with CO-OCS and SO-OCS (40 mM) for 72-h and
subsequently subjected to double staining with annexin V FITC
and propidium Iodide (PI) followed by flow cytometry analysis.
Only annexin V–stained cells were considered as apoptotic cells.
The apoptotic cell percentage increased from 9.7461.24% to
22.5265% for MCF-7 cells (Figure 5A, B, p,0.01) and from
8.261.57% to 26.8564.9% for MDA-MB-231 cells (Figure 5C,
D, p,0.01). To confirm this result we quantified the expression of
the anti-apoptotic protein Bcl-2 and the pro-apoptotic protein Bax
in cells treated with CO-OCS. The Bax to Bcl-2 ratio determines
cellular survival or apoptotic cell death [46,47]. The Bax/Bcl-2
ratio was increased by 2.860.7-folds in MCF-7 (Figure 5E,
p,0.05), and 3.4660.53-folds in MDA-MB-231 cells (Figure 5F,
p,0.01) treated by CO-OCS when compared to the control. In
contrast, SO-OCS induced apoptosis only in MCF-7 cells. The
level of apoptosis increased from 11.9567.78 to 19.0269.4 (Figure
6A, p,0.05), but it did not cause any considerable apoptotic effect
in MDA-MB-231 cells (Figure 6B). Furthermore, the ratios of Bax
to Bcl-2 protein expression revealed that cells treated with 40 mM
of SO-OCS showed a 1.560.19-folds increase in MCF-7 (Figure
6C-a).
We also investigated the effect of SO-OCS and CO-OCS on
apoptosis in MCF-10A by flow cytometry using Annexin V,
Propidium Iodide double-staining. Neither SO-OCS nor CO-
OCS affects apoptosis (Figure S1 A-B). Taken together, these
findings demonstrate an important role for the Bcl2 family of
proteins in CO-OCS induced apoptotic cell death in cancer cells.
Discussion
Several studies have explored the anti-tumour effect of the
indolizidine alkaloid castanospermine and related iminosugar-type
Table 1. IC50 value determined after treatment with the C-
glycoside CO-OCS and the S-glycoside SO-OCS in complete
medium for 72-h.
MCF-7 MDA-MB-231
CO-OCS 26 mM 44 mM
SO-OCS 37 mM 35 mM
doi:10.1371/journal.pone.0076411.t001
Table 2. Percentage of normal and malignant breast cells
treated with CO-OCS and SO-OCS in G0/G1, S, and G2/M
phases of the cell cycle.
phase CTL CO-OCS CTL SO-OCS
G0/G1 60.2562.17 67.8661.9 60.3362.2 52.561.8
MCF-7 S 22.862.3 9.862 20.760.75 17.0761.9
G2/M 17.862.8 2262 18.7562.5 30.3861.4
G0/G1 65.4663.1 50.7660.62 61.9661.8 46.8962.2
MDA-MB-231 S 22.2561.4 19.8861.05 21.9561.16 22.7461.27
G2/M 12.3063.2 30.1261.3 16.1761.42 30.0161.45
G0/G1 61.8762.8 61.8862.3 60.9265 63.9564
MCF-10A S 22.9263.28 22.961.87 20.7964.6 17.2362.8
G2/M 15.1860.68 15.1261.18 18.2763.5 18.7962.6
doi:10.1371/journal.pone.0076411.t002
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Figure 2. CO-OCS and SO-OCS arrested cell cycle at specific phases in breast cancer cell lines but not in normal cell line. Cells were
treated with CO-OCS or SO-OCS (40 mM) for 72-h. Thereafter, cells were collected by trypsinization, stained with propidium iodide and the DNA
content was measured by flow cytometry. The percentage of cells within G0/G1, S, G2/M, were determined. CO-OCS accumulated cells in the G0/G1
and G2/M phases in MCF-7cells (A), and in G2/M phase in MDA-MB-231 cells (B). However, SO-OCS accumulated cells in G2/M phase in both MCF-7
and MDA-MB-231 cells (D, E). No synchronization was observed in MCF-10A cells (C, F). The results represent means 6 SD of three independent
experiments. Inserts: traces representing distribution of the cells in the cell cycle. Asterisks denote statistical significance as compared to control cells
*p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0076411.g002
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glycosidase inhibitors in vitro. Thus, CS inhibits tumor cell invasion
and migration [34] and angiogenesis [33,48]. The administration,
in vivo, of CS during the early phase of tumor growth in mice
delayed the growth of murine and human prostate cancer cells
[33] and reduced pulmonary colonization of metastatic murine
melanoma cells [31]. The anticancer activity of the iminosugars
Figure 3. Effect of CO-OCS and SO-OCS on the expression of G1 and G2/M key proteins in MCF-7 cells. MCF-7 cells were treated with
CO-OCS and SO-OCS (40 mM) for 72h. Cells were harvested at the indicated times and lysed in RIPA buffer. Cell lysates were analyzed by Western
blotting using primary antibodies directed against CDK4, cyclin D1 (A), cyclin E (A), p21Waf1/Cip1 (C), and cyclin B1 proteins (D). B, Effect of CO-OCS on
phosphorylated Rb protein (ppRb) vs Rb protein (pRb). For each protein, a representative immunoblot of three independent experiments is shown
(left panel). Protein levels were quantified and normalized to actin or pRb (right panel). The indicated values are the mean6 SD of three independent
experiments (right panel). *p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0076411.g003
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has been generally ascribed to its ability to inhibit ER and Golgi
neutral glycosidases, thereby affecting the biosynthesis of the
glycan chains in N-glycoproteins, although the mechanisms at play
remain poorly known. The broad range glycosidase inhibitory
profile generally exhibited by iminosugars, particularly the
simultaneous inhibition of the lysosomal acid glycosidase isoen-
zymes, hampers their application in the clinics [49]. In a
preliminary study [41], we reported the synthesis of CS-related
sp2-iminosugars with pseudo-glycoside structure as selective
inhibitors of neutral a-glucosidases. Notably, the pseudo-C- and
pseudo-S-octyl glycosides CO-OCS and SO-OCS significantly
inhibited proliferation of MCF-7 breast cancer cells in vitro.
Contrary to the parent iminosugar CS, none of these sp2-
iminosugars affected human lysosomal acid a-glucosydase or
intestinal maltase-glucoamylase, which reduces the risk of
unwanted secondary effects. Exploring the molecular basis and
biochemical routes responsible for the antiproliferative activity of
CO-OCS and SO-OCS was, thus, very propitious.
Figure 4. Effect of CO-OCS and SO-OCS on the expression of G1 and G2/M key proteins in MDA-MB-231 and MCF-10A cells. MDA-
MB-231 cells were incubated with CO-OCS or SO-OCS (40 mM) for 72-h. Immunoblots showed a decrease in CDK1 (cdc2) expression, but not in cyclin
B1 expression (A). B, Protein levels were quantified and normalized to actin. C, Representative immunoblots of three independent experiments in
MCF-10 A cells. Both CO-OCS and SO-OCS were without effect on the expression of CDK4, CDK1 (cdc2), cyclin D1, cyclin E and cyclin B1 protein. The
results represent mean 6 SD of three independent experiments. **p,0.01.
doi:10.1371/journal.pone.0076411.g004
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In this study we have investigated the mechanisms operating in
the anti-cancer activity induced by the CS-related sp2-iminosugar
pseudo-C- and pseudo-S-octyl glycosides CO-OCS and SO-OCS
in (BC). We show that CO-OCS and SO-OCS reduce BC cell
viability with different sensitivity. The pseudo-C-glycoside CO-
OCS is more potent in inhibiting non-invasive MCF-7 (IC50 =
26 mM) than invasive MDA-MB-231 BC cells (IC50 = 44 mM),
while the pseudo-S-glycoside SO-OCS has similar inhibitory
potencies for both cell lines (IC50 about 35 mM). Moreover, CO-
OCS is more efficient than SO-OCS at inhibiting proliferation of
MCF-7 cells, while the two compounds present similar inhibitory
potencies against MDA-MB-231 cells.
The sp2-iminosugar glycosides CO-OCS and SO-OCS are able
to induce cell cycle arrest and apoptosis in triple positive MCF-7
and triple negative MDA-MB-231 cells, while they exert no effect
on normal breast MCF-10A cells even at high concentrations.
Cyclins and CDKs are the key regulators of the cell cycle G1
phase, the G1/S transition and G2/M phase [50]. Our flow
cytometry analysis shows that CO-OCS induces cell cycle arrest at
the G0/G1 phase in MCF-7 and G2/M in MDA-MB-231 cells;
while SO-OCS induces an arrest in G2/M in both cell lines. The
G0/G1 block obtained upon treatment with CO-OCS is due to a
reduction in CDK4, cyclin D1 and cyclin E expression, a
reduction in pRb phosphorylation and an upregulation of
p21CIP1expression. Indeed, cyclin D1 plays an important role in
controlling the G0/G1 progression and G1/S transition of the cell
cycle by activating their cyclin–dependent kinases (CDK4 and
CDK2) and cyclin E, which leads to phosphorylation of the
retinoblastoma protein (pRb) and, in turn, let the cells to progress
through the G1 phase of the cell cycle [51,52]. The block at G2/
M phase induced by the C-octyl glycoside CO-OCS in MDA-MB-
231 cells and by the S-octyl glycoside SO-OCS in the MCF-7 and
MDA-MB-231cell lines was accompanied by a decrease of CDK1
(cdc2) expression, without affecting the expression of cyclin B1.
Both CO-OCS and SO-OCS are potent inhibitors of ER
neutral a-glycosidase (Ki 0.87 and 3.4 mM, respectively, for the
yeast enzyme). It is well known that the N-glycosylation process
participates in the folding of quality control of proteins synthesized
via ER [53]and that the inhibition of this process can lead to
accumulation of misfolded proteins within the ER that trigger the
UPR [54]. The UPR coordinates the induction of ER chaperones
with decreased protein synthesis and growth arrest in the G1 phase
of the cell cycle which likely serves as a stress-induced response
that allows cells to reestablish ER homeostasis [27,55,56,57].
Several studies have demonstrated the cyclin D1 as a crucial
downstream in UPR-induced cell cycle arrest. Indeed, unfolded
protein response inhibits cyclin D1 translation and expression in
mouse NIH3T3 fibroblasts [56,57]. Loss of cyclin D1 expression
was also observed in several types of human cancer cells lines
treated with a-glucosidase inhibitors, such as N-methyl-1-deox-
ynojirimycin (MDNJ) and N- [8-(3-ethynylphenoxy) octyl]-1-
deoxynojirimycin [58,59], or tunicamycin, the classical and the
most used inhibitor of N-glycosylation [60,61]. Moreover,
overexpression of cyclin D1 prevented cell-cycle arrest at higher
concentrations of tunicamycin, as well as by thapsigargin,
indicating a general role for cyclin D1 loss in UPR-induced arrest
[56]. However, a recent study, in melanoma cells, has demon-
strated the involvement of p27 (increase of expression) rather than
cyclin D1 in G1 cell cycle arrest induced by tunicamycin [62] and
another study, in human breast cancer cells, showed that
knockdown of PERK, results in cell cycle arrest in G2/M phase
[63]. Given that ER stress-mediated activation of the UPR occurs
in cancer tissues and cell lines [64,65,66], we can hypothesized
that the observed effects of the CS-related sp2-iminosugar
glycosides in BC cells cycle, that is the blockade at G1 in MCF-
7 and at G2/M in MDA-MB-231 cells by CO-OCS and at G2/M
in either of the two BC cell lines by SO-OCS, constitute an
adaptive response for survival, although the molecular mecha-
nisms remain to be determined.
CO-OCS and SO-OCS induced cellular mortality that was
mainly apoptotic as demonstrated by the increased percentage of
annexin V positive cells and Bax/Bcl-2 ratio in MCF-7 and MDA-
MB231cells. The C-octyl glycoside CO-OCS is more potent than
the S-octyl glycoside congener SO-OCS, which failed to induce
apoptosis in MDA-MB-231 cells. Several members of the proteins
that control apoptosis, including the anti-apoptotic protein Bcl2
and the pro-apoptotic protein Bax are expressed in breast
carcinoma [67,68]. Our results show a relationship between the
type of apoptosis (precocious or delayed) and the expression of
Bcl2 and Bax. CO-OCS increased precocious apoptosis in MCF-7
that was associated with a decrease in the expression of Bcl2
expression and an increase in Bax expression. However, in MDA-
MB-23 it induced a delayed apoptosis which is associated with a
reduction of Bcl2 but without any significant effect on Bax
expression. Similar result was obtained with SO-OCS in MCF-7
cells.
Several studies have proposed the polyhydroxylated alkaloids as
apoptotic inducers in cancer cells. Indeed, swainsonine (SW), a
natural indolizidine alkaloid with strong Golgi a-mannosidase II
inhibitory activity, induces apoptosis in human gastric, lung, and
oesophageal squamous cancer cells through the activation of
mitochondrial pathway. In human gastric carcinoma cells and rat
glioma cells, SW induces apoptosis by involving Ca2+ overload and
Bcl-2 expression decrease [69,70]. These authors reported recently
that SW treatment induces oesophageal squamous cancer cells
apoptosis by up-regulating Bax and down-regulating Bcl-2
expression [71]. The fact that both sp2-iminosugars CO-OCS
and SO-OCS behave as inhibitors of ER a-glucosidases and also
regulate the expression of Bcl2 and Bax supports a relationship
between the N-glycoprotein biosynthesis and ER stress-associated
apoptotic effect, although alternative mechanistic pathways cannot
be discarded. Thus, it is known that a decrease in the expression of
CDK1 along with an increase in that of p21waf1/cip1 may lead to
apoptosis [72]. Since CO-OCS and SO-OCS decrease the
expression of CDK1 in both MCF-7 and MDA-MB231 and
CO-OCS increases p21waf1/cip1 expression in MCF-7 cells, we
cannot exclude the involvement of these actors in apoptosis.
In summary, the biological evaluation of sp2-iminosugar-type
castanospermine analogues led to the identification of the C- and
S-octyl glycosides CO-OCS and SO-OCS as inhibitors of breast
cancer cell growth in vitro. The two substances inhibit tumor cells
proliferation by inducing cell cycle arrest and induce apoptosis,
displaying a range of properties of interest in the development of
new antitumor agents.
Figure 5. CO-OCS induced apoptosis in MCF-7 and MDA-MB-231 cell lines. Cells were treated with CO-OCS for 72-h and the apoptosis assay
was carried out by annexin V staining. CO-OCS (40 mM) induces apoptosis in both MCF-7 (A, B) and MDA-MB-231 cells (C, D). Representative traces of
three independent experiments are shown on the left panel. The indicated values are the mean6 SD of three independent experiments (right panel)
** p,0.01. E, F, Treatment with CO-OCS increases the ratio Bax/Bcl2 in MCF-7 (E) and MDA-MB-231 cells (F). All experiments were performed at least
three times in independent cell culture. *,** significantly different form control at p,0.05, and 0.01 respectively.
doi:10.1371/journal.pone.0076411.g005
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Figure 6. SO-OCS induced apoptosis in MCF-7 cells but not in MDA-MB-231 cells. A Representative apoptosis assay carried out by annexin V
staining after 72-h treatment of MCF-7 (A) and MDA-MB-231 cells (B) with SO-OCS at concentration of 40 mM. C, Representative Western blot showing
the effect of SO-OCS on Bax and Bcl-2 expression in MCF-7 cells (C-a) and MDA-MB-231 cells (C-b). All experiments were performed at least three
times in independent cell cultures. * Significantly different from control at p,0.05.
doi:10.1371/journal.pone.0076411.g006
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Supporting Information
Figure S1 A representative apoptosis assay carried out using
annexin V staining after 72-h treatment of MCF-10A with 40 mM Co-
ocs (B) and 40 mM So-ocs (C). Both Co-ocs and So-ocs failed to induce
apoptosis when compared to control conditions (A). Experiments were
performed 2 times in 2 independent cell culture conditions.
(TIF)
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